AF
CTMX icon

Allworth Financial’s CytomX Therapeutics CTMX Stock Holding History

Allworth Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06K Buy
282
+245
+662% +$935 ﹤0.01% 4702
2026
Q1 		$174 Buy
+37
New +$188 ﹤0.01% 4945

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Allworth Financial's CTMX Position: Q2 2026 in Review

Allworth Financial increased its CytomX Therapeutics (CTMX) stake by 662% in Q2 2026, buying an estimated $935 and bringing the position to 282 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4702.

Allworth Financial first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Allworth Financial held 282 shares of CytomX Therapeutics worth $1.06K as of Q2 2026.
  • Allworth Financial bought 245 CytomX Therapeutics shares in Q2 2026, an estimated $935.
  • CytomX Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4702 holding.
  • Allworth Financial first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.